PMID- 36052284
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220907
IS  - 1687-8450 (Print)
IS  - 1687-8469 (Electronic)
IS  - 1687-8450 (Linking)
VI  - 2022
DP  - 2022
TI  - Phosphatidylinositol 3-Kinase/Protein Kinase B/Mammalian Target of the Rapamycin 
      Pathway-Related Protein Expression in Lung Squamous Cell Carcinoma and Its 
      Correlation with Lymph Node Metastasis.
PG  - 4537256
LID - 10.1155/2022/4537256 [doi]
LID - 4537256
AB  - The targeted therapy of lung squamous cell carcinoma (LSCC), a pathological type 
      of non-small-cell lung cancer, is relatively lacking by contrast with lung 
      adenocarcinoma. The overexpression or inhibition of intracellular signaling 
      pathways leads to disease. To evaluate genes for a targeted therapy in LSCC, we 
      analyzed PI3K pathway components in LSCC tissues and found elevated PI3K levels 
      in LSCC tissues compared with adjacent counterparts. A comparison of PI3K levels 
      in tissues with and without metastasis revealed that the PI3K pathway activity 
      was greatly increased in metastatic tissues. Our findings suggest that the 
      metastasis of cancer cells in patients with LSCC is closely related to the 
      overexpression of PI3K pathway components in cancer tissues. We performed in 
      vitro cell culture experiments and found that inhibition of PI3K activity 
      decreased proliferation and increased apoptosis in H520 cells, suggesting that 
      PI3K pathway inhibition limits LSCC cell proliferation. We hypothesize that LSCC 
      metastasis is related to the overexpression of PI3K pathway components and 
      inhibiting this pathway may help reduce the risk of lymph node metastasis in LSCC 
      patients.
CI  - Copyright (c) 2022 Fang Shi and Ling Li.
FAU - Shi, Fang
AU  - Shi F
AUID- ORCID: 0000-0003-4991-3460
AD  - Department of Oncology, Jiangxi Chest Hospital, Nanchang 330006, Jiangxi, China.
FAU - Li, Ling
AU  - Li L
AD  - Department of Oncology, Second Affiliated Hospital of Nanchang University, 
      Nanchang 330006, Jiangxi, China.
LA  - eng
PT  - Journal Article
DEP - 20220823
PL  - Egypt
TA  - J Oncol
JT  - Journal of oncology
JID - 101496537
PMC - PMC9427249
COIS- The authors declare that they have no conflicts of interest.
EDAT- 2022/09/03 06:00
MHDA- 2022/09/03 06:01
PMCR- 2022/08/23
CRDT- 2022/09/02 02:49
PHST- 2022/06/02 00:00 [received]
PHST- 2022/06/29 00:00 [revised]
PHST- 2022/07/08 00:00 [accepted]
PHST- 2022/09/02 02:49 [entrez]
PHST- 2022/09/03 06:00 [pubmed]
PHST- 2022/09/03 06:01 [medline]
PHST- 2022/08/23 00:00 [pmc-release]
AID - 10.1155/2022/4537256 [doi]
PST - epublish
SO  - J Oncol. 2022 Aug 23;2022:4537256. doi: 10.1155/2022/4537256. eCollection 2022.